Alzheimer disease, inflammation, and novel inflammatory marker: resistin

Background/aim: Inflammation may play an important role in Alzheimer disease (AD) pathogenesis. A growing amount of evidence indicates that resistin has hallmark regulatory functions such as inflammatory states. The aim of this study was to determine whether plasma resistin levels would be useful in the diagnosis of patients with AD and to investigate the relationships between resistin and other inflammatory markers such as hs-CRP and TNF-α. Materials and methods: In this cross-sectional study, 38 AD patients and 32 control subjects with normal cognitive function aged 65 years and over were included. The diagnosis of AD was made according to DSM-IV and NINCDS-ADRDA criteria. Serum levels of resistin were measured with an enzyme-linked immunosorbent assay method using the human resistin E50 kit. Results: The median resistin level of AD patients was significantly higher than in the control group (86.3 vs. 70.8 pg/mL, P = 0.002). Overall accuracy of resistin in determining AD was 70.66%, with sensitivity, specificity, PPV, and NPV of 75.0%, 65.5%, 73.0%, and 67.9%, respectively. There was no statistically significant difference between AD patients and control subjects with respect to hs-CRP and TNF-α levels. Conclusion: Resistin levels may be considered as a predictor of AD and it may predict activation of the immune system in AD pathophysiology.

Alzheimer disease, inflammation, and novel inflammatory marker: resistin

Background/aim: Inflammation may play an important role in Alzheimer disease (AD) pathogenesis. A growing amount of evidence indicates that resistin has hallmark regulatory functions such as inflammatory states. The aim of this study was to determine whether plasma resistin levels would be useful in the diagnosis of patients with AD and to investigate the relationships between resistin and other inflammatory markers such as hs-CRP and TNF-α. Materials and methods: In this cross-sectional study, 38 AD patients and 32 control subjects with normal cognitive function aged 65 years and over were included. The diagnosis of AD was made according to DSM-IV and NINCDS-ADRDA criteria. Serum levels of resistin were measured with an enzyme-linked immunosorbent assay method using the human resistin E50 kit. Results: The median resistin level of AD patients was significantly higher than in the control group (86.3 vs. 70.8 pg/mL, P = 0.002). Overall accuracy of resistin in determining AD was 70.66%, with sensitivity, specificity, PPV, and NPV of 75.0%, 65.5%, 73.0%, and 67.9%, respectively. There was no statistically significant difference between AD patients and control subjects with respect to hs-CRP and TNF-α levels. Conclusion: Resistin levels may be considered as a predictor of AD and it may predict activation of the immune system in AD pathophysiology.

___

  • Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009; 28: 281–287. 7. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging 2007; 28: 1810–1820.
  • Zhou L, Li Y, Xia T, Feng S, Chen X, Yang Z. Resistin overexpression impaired glucose tolerance in hepatocytes. Eur Cytokine Netw 2006; 17: 189–195.
  • Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009; 133: 157–170.
  • Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, Parhofer KG, Göke B, Broedl UC. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007; 19: 1070–1074.
  • Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286–290.
  • Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452–5455.
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
  • Stähelin HB, Monsch AU, Spiegel R. Early diagnosis of dementia via a two-step screening and diagnostic procedure. Int Psychogeriatr 1997; 9: 123–130.
  • Rabe-Jabłońska J, Bieńkiewicz W. Anxiety disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association: diagnostic and statistical manual of mental disorders (DMS-IV -- options book. Psychiatr Pol 1994; 28: 255–268 (in Polish with English abstract).
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.
  • Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789–5795.
  • Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: 45.
  • Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007; 92: 2272–2279.
  • Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, De Manzoni G, Lippi G, Guidi GC. The role of resistin in colorectal cancer. Clin Chim Acta 2012; 413: 760–764.
  • Schindler K, Vila G, Hoppichler F, Lechleitner M, Luger A, Anderwald C, Hoefler J, Tomasec G, Kautzky-Willer A, Ludvik B. The impact of type 2 diabetes on circulating adipokines in patients with metabolic syndrome. Obes Facts 2012; 5: 270– 276.
  • McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006; 17: 170–175.
  • Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A et al. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 2006; 364: 91–112.
  • Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res 2000; 887: 80–89.
  • Richartz E, Batra A, Simon P, Wormstall H, Bartels M, Buchkremer G, Schott K. Diminished production of proinflammatory cytokines in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 184–188.
  • Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50: 2041–2056.
  • Brugg B, Dubreuil YL, Huber G, Wollman EE, Delhaye- Bouchaud N, Mariani J. Inflammatory processes induce beta- amyloid precursor protein changes in mouse brain. P Natl Acad Sci USA 1995; 92: 3032–3035.
  • Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14: 133–145.
  • Dziedzic T. Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen 2006; 21: 258–262.
  • Duong T, Nikolaeva M, Acton PJ. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer’s disease. Brain Res 1997; 749: 152–156.
  • Iwamoto N, Nishiyama E, Ohwada J, Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994; 177: 23–26.
  • Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2009; 30: 1885–1889.
  • Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Aβ1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 2003; 105: 135–144.
  • Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76– 80.
  • Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhİj P, Pedersen BK. A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999; 54: 357–364.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

Impaired cognitive performance and hippocampal atrophy in Parkinson disease

DEMET YILDIZ, SEVDA ERER, MEHMET ZARİFOĞLU, BAHATTİN HAKYEMEZ, MUSTAFA BAKAR, NECDET KARLI, ZEYNEP NİGAR VARLIBAŞ, FATİH TUFAN

Why is Alzheimer disease confused with other dementias?

İbrahim Levent GÜNGÖR, Dursun AYGÜN

The reliability and validity of the Turkish version of theNeuropsychiatric Inventory-Clinician

Eylem Şahin CANKURTARAN, Mustafa DANIŞMAN, Hasan TUTAR, Semra Ulusoy KAYMAK

Postoperative cognitive dysfunction and Alzheimer disease

BERRİN IŞIK

Vitamin D status and its association with gradual decline in cognitive function

YUSUF YEŞİL, MEHMET EMİN KUYUMCU, ÖZGÜR KARA, BURÇİN HALAÇLI, SEZGİN ETGÜL, MUHAMMET CEMAL KIZILARSLANOĞLU, BURCU BALAM YAVUZ, MÜNEVVER ÖZCAN, MELTEM GÜLHAN HALİL, EYLEM ŞAHİN CANKURTARAN, MUSTAFA CANKURTARAN, SERVET ARIOĞUL

Preface - Special Issue on: Alzheimer Disease: From Bench to Bedside'

MARK S KINDY, ÖMER AKYOL, KUMAR SAMBAMURTI

A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease

Nuriye Nuray ULUSU, Gökhan YILMAZ, Zübeyde ERBAYRAKTAR, Ahmet Turan EVLİCE, Sevgi ARAS, Görsev YENER, Aslihan AVCI

Cognitive problems related to vertebrobasilar circulation

Abdulkadir KOÇER

Malnutrition is associated with dementia severity and geriatricsyndromes in patients with Alzheimer disease

Demet YILDIZ, Nilüfer Büyükkoyuncu PEKEL, Ahmet Kasim KILIÇ, Elif Nalan TOLGAY, Fatih TUFAN

A comparison of hair and serum trace elements in patients with Alzheimer disease and healthy participants

EMİNE RABİA KOÇ, ATİLLA İLHAN, ZÜBEYDE AYTÜRK, BURCU ACAR, MUKADDES GÜRLER, AYNUR ALTUNTAŞ, MUSTAFA KARAPİRLİ, ABDURRAHMAN SAİD BODUR